000164658 001__ 164658
000164658 005__ 20230915090555.0
000164658 0247_ $$2pmc$$apmc:PMC9162044
000164658 0247_ $$2doi$$a10.1212/WNL.0000000000200257
000164658 0247_ $$2ISSN$$a0028-3878
000164658 0247_ $$2ISSN$$a1526-632X
000164658 0247_ $$2altmetric$$aaltmetric:126089582
000164658 0247_ $$2pmid$$apmid:35264424
000164658 037__ $$aDZNE-2022-01188
000164658 082__ $$a610
000164658 1001_ $$0P:(DE-2719)2814101$$aWilke, Carlo$$b0$$eFirst author$$udzne
000164658 245__ $$aLevels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1
000164658 260__ $$a[S.l.]$$bOvid$$c2022
000164658 3367_ $$2DRIVER$$aarticle
000164658 3367_ $$2DataCite$$aOutput Types/Journal article
000164658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655284052_27752
000164658 3367_ $$2BibTeX$$aARTICLE
000164658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164658 3367_ $$00$$2EndNote$$aJournal Article
000164658 520__ $$aNeurofilament light (NfL) appears to be a promising fluid biomarker in repeat-expansion spinocerebellar ataxias (SCAs), with piloting studies in mixed SCA cohorts suggesting that NfL might be increased at the ataxic stage of SCA type 1 (SCA1). We here hypothesized that NfL is increased not only at the ataxic stage of SCA1, but also at its (likely most treatment-relevant) preataxic stage.Methods We assessed serum NfL (sNfL) and CSF NfL (cNfL) levels in both preataxic and ataxic SCA1, leveraging a multicentric cohort recruited at 6 European university centers, and clinical follow-up data, including actually observed (rather than only predicted) conversion to the ataxic stage. Levels of sNfL and cNfL were assessed by single-molecule array and ELISA technique, respectively.Results Forty individuals with SCA1 (23 preataxic, 17 ataxic) and 89 controls were enrolled, including 11 preataxic individuals converting to the ataxic stage. sNfL levels were increased at the preataxic (median 15.5 pg/mL [interquartile range 10.5–21.1 pg/mL]) and ataxic stage (31.6 pg/mL [26.2–37.7 pg/mL]) compared to controls (6.0 pg/mL [4.7–8.6 pg/mL]), yielding high age-corrected effect sizes (preataxic: r = 0.62, ataxic: r = 0.63). sNfL increases were paralleled by increases of cNfL at both the preataxic and ataxic stage. In preataxic individuals, sNfL levels increased with proximity to predicted ataxia onset, with significant sNfL elevations already 5 years before onset, and confirmed in preataxic individuals with actually observed ataxia onset. sNfL increases were detected already in preataxic individuals with SCA1 without volumetric atrophy of cerebellum or pons, suggesting that sNfL might be more sensitive to early preataxic neurodegeneration than the currently known most change-sensitive regions in volumetric MRI. Using longitudinal sNfL measurements, we estimated sample sizes for clinical trials with the reduction of sNfL as the endpoint.Discussion sNfL levels might provide easily accessible peripheral biomarkers in both preataxic and ataxic SCA1, allowing stratification of preataxic individuals regarding proximity to onset, early detection of neurodegeneration even before volumetric MRI alterations, and potentially capture of treatment response in clinical trials.Trial Registration Information ClinicalTrials.gov Identifier: NCT01037777.Classification of Evidence This study provides Class III evidence that NfL levels are increased in both ataxic and preataxic SCA1 and are associated with ataxia onset.
000164658 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164658 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000164658 650_2 $$2MeSH$$aAtrophy: pathology
000164658 650_2 $$2MeSH$$aBiomarkers
000164658 650_2 $$2MeSH$$aCerebellar Ataxia: pathology
000164658 650_2 $$2MeSH$$aCerebellum: pathology
000164658 650_2 $$2MeSH$$aHumans
000164658 650_2 $$2MeSH$$aIntermediate Filaments
000164658 650_2 $$2MeSH$$aNeurofilament Proteins
000164658 650_2 $$2MeSH$$aSpinocerebellar Ataxias: diagnosis
000164658 7001_ $$0P:(DE-2719)9000375$$aMengel, David$$b1$$udzne
000164658 7001_ $$0P:(DE-2719)2810795$$aSchöls, Ludger$$b2$$udzne
000164658 7001_ $$0P:(DE-2719)2811940$$aHengel, Holger$$b3$$udzne
000164658 7001_ $$aRakowicz, Maria$$b4
000164658 7001_ $$0P:(DE-2719)2810314$$aKlockgether, Thomas$$b5$$udzne
000164658 7001_ $$0P:(DE-2719)9000429$$aDürr, Alexandra$$b6$$udzne
000164658 7001_ $$aFilla, Alessandro$$b7
000164658 7001_ $$aMelegh, Bela$$b8
000164658 7001_ $$0P:(DE-2719)2812018$$aSchüle, Rebecca$$b9$$udzne
000164658 7001_ $$aReetz, Kathrin$$b10
000164658 7001_ $$0P:(DE-2719)2811564$$aJacobi, Heike$$b11$$udzne
000164658 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b12$$eLast author$$udzne
000164658 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000200257$$gVol. 98, no. 20, p. e1985 - e1996$$n20$$pe1985 - e1996$$tNeurology$$v98$$x0028-3878$$y2022
000164658 909CO $$ooai:pub.dzne.de:164658$$pVDB
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814101$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000375$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810795$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811940$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810314$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000164658 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000429$$aExternal Institute$$b6$$kExtern
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812018$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811564$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000164658 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000164658 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164658 9141_ $$y2022
000164658 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000164658 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000164658 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000164658 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2022-11-12$$wger
000164658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2021$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000164658 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEUROLOGY : 2021$$d2022-11-12
000164658 9201_ $$0I:(DE-2719)1240005$$kCore ICRU$$lCore ICRU$$x0
000164658 9201_ $$0I:(DE-2719)1210000$$kAG Gasser 1$$lParkinson Genetics$$x1
000164658 9201_ $$0I:(DE-2719)1011001$$kAG Klockgether$$lClinical Research- coordination$$x2
000164658 9201_ $$0I:(DE-2719)5000024$$kAG Maetzler$$lFunctional Neurogeriatrics$$x3
000164658 9201_ $$0I:(DE-2719)1011101$$kPatient studies, Bonn$$lPatient studies$$x4
000164658 980__ $$ajournal
000164658 980__ $$aVDB
000164658 980__ $$aI:(DE-2719)1240005
000164658 980__ $$aI:(DE-2719)1210000
000164658 980__ $$aI:(DE-2719)1011001
000164658 980__ $$aI:(DE-2719)5000024
000164658 980__ $$aI:(DE-2719)1011101
000164658 980__ $$aUNRESTRICTED